Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

NCT03724240 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

624

Enrollment

INDUSTRY

Sponsor class

Conditions

Hay Fever

Interventions

BIOLOGICAL: Placebo solution
BIOLOGICAL: gpASIT+TM

Sponsor

ASIT Biotech S.A.